Abstract
Stroke is a major cause of mortality and morbidity worldwide. There are two approaches to treat stroke, a neuroprotective approach that focuses on reducing the lesion and a neurorestorative one, designed to promote neurological recovery by treating the entire central nervous system (CNS). To date, clinical trials of neuroprotective agents for stroke have failed. Recently, cell-based and pharmacological neurorestorative therapies have shown enormous promise in reducing neurological deficits caused by stroke. This article will briefly describe preclinical studies on how the injured CNS can be stimulated by cell-based and pharmacological therapies to amplify its intrinsic restorative processes and thereby lead to improvement in neurological function post-stroke.